Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
Revive Therapeutics (OTCQB: RVVTF) is nearing completion of a crucial study evaluating Bucillamine as a nerve agent countermeasure in partnership with Defence R&D Canada (DRDC). The study is set to conclude by September 2025, with potential Health Canada approval for strategic stockpiling by 2026.
Bucillamine, a thiol-based drug with proven safety profile, works by replenishing glutathione to protect the brain and organs from toxic exposures. The company aims to expand its applications to include traumatic brain injury (TBI) and viral infections. The successful development could position Revive for significant government stockpiling contracts with Canada and its "Five Eyes" intelligence partners.
Revive Therapeutics (OTCQB: RVVTF) sta per completare uno studio fondamentale che valuta Bucillamina come contromisura agli agenti nervini, in collaborazione con Defence R&D Canada (DRDC). Lo studio è previsto concludersi entro settembre 2025, con una possibile approvazione da parte di Health Canada per lo stoccaggio strategico entro il 2026.
La Bucillamina, un farmaco a base di tioli con un profilo di sicurezza comprovato, agisce ripristinando il glutatione per proteggere cervello e organi da esposizioni tossiche. L'azienda mira a estendere le sue applicazioni includendo il trauma cranico (TBI) e le infezioni virali. Un successo nello sviluppo potrebbe posizionare Revive per importanti contratti di stoccaggio governativo con il Canada e i suoi partner dell'intelligence "Five Eyes".
Revive Therapeutics (OTCQB: RVVTF) está cerca de completar un estudio crucial que evalúa Bucilamina como contramedida contra agentes nerviosos, en colaboración con Defence R&D Canada (DRDC). El estudio se espera que concluya para septiembre de 2025, con posible aprobación de Health Canada para almacenamiento estratégico en 2026.
La Bucilamina, un fármaco basado en tioles con un perfil de seguridad comprobado, actúa reponiendo glutatión para proteger el cerebro y órganos de exposiciones tóxicas. La compañía busca ampliar sus aplicaciones para incluir lesiones cerebrales traumáticas (TBI) e infecciones virales. Un desarrollo exitoso podría posicionar a Revive para contratos importantes de almacenamiento gubernamental con Canadá y sus socios de inteligencia "Five Eyes".
Revive Therapeutics (OTCQB: RVVTF)는 Defence R&D Canada(DRDC)와 협력하여 신경작용제 대응제로서 Bucillamine을 평가하는 중요한 연구를 거의 마무리하고 있습니다. 이 연구는 2025년 9월까지 완료될 예정이며, 2026년까지 Health Canada의 전략적 비축 승인 가능성이 있습니다.
티올 기반 약물인 Bucillamine은 안전성이 입증된 약물로, 글루타티온을 보충하여 뇌와 장기를 독성 노출로부터 보호합니다. 회사는 이를 외상성 뇌손상(TBI) 및 바이러스 감염으로 적용 범위를 확장하는 것을 목표로 하고 있습니다. 성공적인 개발은 Revive가 캐나다 및 "Five Eyes" 정보 동맹국들과의 정부 비축 계약에서 중요한 위치를 차지할 수 있게 할 것입니다.
Revive Therapeutics (OTCQB : RVVTF) est sur le point de terminer une étude cruciale évaluant la Bucillamine comme contre-mesure aux agents neurotoxiques en partenariat avec Defence R&D Canada (DRDC). L'étude devrait se conclure d'ici septembre 2025, avec une possible approbation de Santé Canada pour un stockage stratégique d'ici 2026.
La Bucillamine, un médicament à base de thiols avec un profil de sécurité éprouvé, agit en reconstituant le glutathion pour protéger le cerveau et les organes des expositions toxiques. La société vise à étendre ses applications aux traumatismes crâniens (TBI) et aux infections virales. Un développement réussi pourrait positionner Revive pour des contrats importants de stockage gouvernemental avec le Canada et ses partenaires du renseignement des "Five Eyes".
Revive Therapeutics (OTCQB: RVVTF) steht kurz vor dem Abschluss einer wichtigen Studie zur Bewertung von Bucillamin als Gegenmaßnahme gegen Nervengifte in Zusammenarbeit mit Defence R&D Canada (DRDC). Die Studie soll bis September 2025 abgeschlossen sein, mit einer möglichen Zulassung durch Health Canada für strategische Vorratshaltung bis 2026.
Bucillamin, ein tiolbasiertes Medikament mit nachgewiesener Sicherheit, wirkt durch Auffüllung von Glutathion, um Gehirn und Organe vor toxischen Einflüssen zu schützen. Das Unternehmen plant, die Anwendung auf traumatische Hirnverletzungen (TBI) und Virusinfektionen auszuweiten. Eine erfolgreiche Entwicklung könnte Revive für bedeutende Regierungsaufträge zur Vorratshaltung mit Kanada und den "Five Eyes"-Geheimdienstpartnern positionieren.
- Partnership with Canadian Department of National Defence adds credibility and clear market pathway
- Potential fast-track approval from Health Canada for stockpiling by 2026
- Bucillamine has well-established safety profile and multiple potential applications
- Large market opportunity through government stockpiling contracts with Five Eyes nations
- Additional potential applications in TBI and viral infections could expand market reach
- Study results are still pending and success is not guaranteed
- Regulatory approval timeline could extend beyond 2026
- Competition from existing nerve agent countermeasures in the market
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury.
After recent discussions with the DRDC, the research study on Bucillamine is now set to conclude by September 2025. With continued promising ongoing results and current DRDC and regulatory initiatives, there are potential pathways for Health Canada to grant faster approval for DRDC strategic stockpiling plans for treating nerve agent or organophosphate pesticide poisoning in 2026. In addition, plans are being pursued to explore the use of Bucillamine in traumatic brain injury (TBI) from concussive/explosive forces and viral infections. In light of current world events, therapeutic options for the battlefield are becoming a high priority for nations involved. Bucillamine has the potential to become a vital option for medical countermeasures and in the battlefield.
Bucillamine: A Promising Medical Countermeasure
Bucillamine is a thiol-based drug with a well-established safety profile and strong anti-inflammatory and antioxidant properties. Its mechanism of action is believed to protect the brain and other organs by replenishing glutathione, the body’s master antioxidant, which is depleted during toxic exposures. This unique property makes Bucillamine a compelling candidate for both preventing and treating the debilitating, long-term neurological damage caused by nerve agents. Its potential applications include:
- Prophylactic (Pre-Exposure) Use: Administering to military personnel and first responders before potential exposure to a nerve agent threat.
- Post-Exposure Treatment: Mitigating the severe brain injury and other organ damage that occurs following an attack, complementing existing therapies.
Urgent Global Need and Substantial Market Opportunity
The threat of chemical weapons, specifically nerve agents, remains a deep concern for governments worldwide.
In today's heightened geopolitical climate, the need for effective medical countermeasures is more critical than ever. Ongoing conflicts, such as those in Ukraine and the Middle East, have placed a renewed focus on soldier survivability and readiness. Bucillamine’s potential to be administered easily on the battlefield could be a game-changer, protecting armed forces from chemical threats and the neurological effects of blast-induced TBI.
Government Stockpiling: A Proven and Lucrative Market
Western governments have well-established programs for stockpiling medical countermeasures to protect their military and civilian populations. Examples include:
- The U.S. Project BioShield Act: This program, managed by agencies like the Biomedical Advanced Research and Development Authority (BARDA), allocates billions of dollars to procure life-saving treatments for chemical, biological, radiological, and nuclear (CBRN) threats.
- Pandemic Preparedness: The recent global response to COVID-19 demonstrated the massive scale at which governments will procure and stockpile vaccines and therapeutics to ensure national security and public health.
Successful approval for Bucillamine as a nerve agent countermeasure would position Revive to pursue significant and lucrative procurement contracts with the Canadian government and its "Five Eyes" intelligence partners (U.S., U.K., Australia, New Zealand), representing a massive market opportunity.
“Our collaboration with DRDC is reaching a critical milestone at a time when the world is acutely aware of the need for robust national defense and preparedness,” said Michael Frank, CEO of Revive Therapeutics. “In a world of increasing geopolitical instability, an effective and easily administered countermeasure like Bucillamine has the potential to protect our service members and first responders. The successful conclusion of this study could unlock a substantial commercial opportunity through government stockpiling contracts and firmly establish Revive as a key player in the medical countermeasure space.”
A Compelling Investment Proposition
Revive Therapeutics offers a unique investment opportunity based on the significant potential of Bucillamine:
- High-Profile Government Partnership: Collaboration with the Canadian Department of National Defence lends significant credibility and a clear path to market.
- Urgent, High-Value Market: The global nerve agent countermeasure market is driven by non-negotiable government defense spending.
- Expedited Regulatory Pathway: Potential for accelerated approval and stockpiling initiatives in 2026.
- Pipeline Expansion: Proven success in this indication could support and fund further development for TBI and viral infections.
The Company will continue to provide updates on its progress with the DRDC study as it nears completion.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025 ("MD&A"), dated May 29, 2025, which is available on the Company's profile at www.sedarplus.ca.
FAQ
When will Revive Therapeutics (RVVTF) complete its nerve agent countermeasure study?
What is Bucillamine and how does it work against nerve agents?
What are the potential market opportunities for RVVTF's Bucillamine?
How could Bucillamine be used in military applications?
What is the significance of RVVTF's partnership with DRDC?
